CAR -T-cell therapy (Allegheny Singer Research Institute)

N/A

Report date: 2023/05/05 17:35:12

Base Information

Drug NameCAR -T-cell therapy (Allegheny Singer Research Institute)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAllegheny Singer Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesAllegheny Singer Research InstituteMiltenyi Biotec GmbHLentigen Technology Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A